{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:55:15Z","timestamp":1788191715238,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.intimp.2022.108623","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T10:55:15Z","timestamp":1645440915000},"page":"108623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma"],"prefix":"10.1016","volume":"106","author":[{"given":"Tianwen","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2022.108623_b0005","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"10.1016\/j.intimp.2022.108623_b0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?","volume":"7","author":"Menetrier-Caux","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"10","key":"10.1016\/j.intimp.2022.108623_b0015","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/fon-2018-0609","article-title":"KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer","volume":"15","author":"Kato","year":"2019","journal-title":"Future oncology (London, England)."},{"issue":"11","key":"10.1016\/j.intimp.2022.108623_b0020","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"issue":"35","key":"10.1016\/j.intimp.2022.108623_b0025","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol."},{"issue":"17","key":"10.1016\/j.intimp.2022.108623_b0030","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108623_b0035","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"The Lancet Oncology."},{"issue":"1","key":"10.1016\/j.intimp.2022.108623_b0040","doi-asserted-by":"crossref","first-page":"100889","DOI":"10.1016\/j.tranon.2020.100889","article-title":"Combination therapy: Future directions of immunotherapy in small cell lung cancer","volume":"14","author":"Huang","year":"2021","journal-title":"Transl Oncol."},{"key":"10.1016\/j.intimp.2022.108623_b0045","doi-asserted-by":"crossref","first-page":"103180","DOI":"10.1016\/j.critrevonc.2020.103180","article-title":"Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives","volume":"157","author":"Mortezaee","year":"2021","journal-title":"Crit Rev Oncol Hematol."},{"issue":"10","key":"10.1016\/j.intimp.2022.108623_b0050","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S1470-2045(18)30662-4","article-title":"Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?","volume":"19","author":"Ilson","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108623_b0055","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jtcvs.2020.11.106","article-title":"Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer","volume":"161","author":"Sihag","year":"2021","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"9","key":"10.1016\/j.intimp.2022.108623_b0060","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/2326-6066.CIR-14-0069","article-title":"Combining radiation and immunotherapy: a new systemic therapy for solid tumors?","volume":"2","author":"Tang","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.intimp.2022.108623_b0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.11.024","article-title":"Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)","volume":"151","author":"Faivre-Finn","year":"2021","journal-title":"Lung Cancer."},{"issue":"31","key":"10.1016\/j.intimp.2022.108623_b0070","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/fon-2020-0222","article-title":"Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma","volume":"16","author":"Yang","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.intimp.2022.108623_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"Journal for immunotherapy of cancer."},{"issue":"12","key":"10.1016\/j.intimp.2022.108623_b0080","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","article-title":"The central role of CD4(+) T cells in the antitumor immune response","volume":"188","author":"Hung","year":"1998","journal-title":"J Exp Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.108623_b0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2022.108623_b0090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/1744666X.2017.1366315","article-title":"Immunotherapy of cancers comes of age","volume":"13","author":"Yousefi","year":"2017","journal-title":"Expert Rev Clin Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108623_b0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-015-2037-1","article-title":"Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma","volume":"127","author":"Mendez","year":"2016","journal-title":"J Neurooncol."},{"issue":"S1","key":"10.1016\/j.intimp.2022.108623_b0100","doi-asserted-by":"crossref","first-page":"E1061","DOI":"10.1002\/hed.24158","article-title":"Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer","volume":"38","author":"Cho","year":"2016","journal-title":"Head Neck."},{"issue":"12","key":"10.1016\/j.intimp.2022.108623_b0105","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1158\/1078-0432.CCR-17-1323","article-title":"Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer","volume":"24","author":"Afghahi","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2022.108623_b0110","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0360-3016(00)00769-0","article-title":"Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix","volume":"48","author":"Santin","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"10.1016\/j.intimp.2022.108623_b0115","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.4049\/jimmunol.139.10.3199","article-title":"Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes","volume":"139","author":"Sellins","year":"1987","journal-title":"J Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108623_b0120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiation research."},{"issue":"5","key":"10.1016\/j.intimp.2022.108623_b0125","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","article-title":"Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer","volume":"105","author":"Cho","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"10.1016\/j.intimp.2022.108623_b0130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2020.01.032","article-title":"Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1\/2 Trials","volume":"108","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"10.1016\/j.intimp.2022.108623_b0135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.radonc.2018.02.025","article-title":"High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer","volume":"128","author":"Fang","year":"2018","journal-title":"Radiother Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108623_b0140","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1634\/theoncologist.2018-0723","article-title":"Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy","volume":"24","author":"Zhou","year":"2019","journal-title":"Oncologist."},{"issue":"1","key":"10.1016\/j.intimp.2022.108623_b0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy","volume":"99","author":"Davuluri","year":"2017","journal-title":"International journal of radiation oncology, biology, physics."},{"key":"10.1016\/j.intimp.2022.108623_b0150","unstructured":". !!! INVALID CITATION !!! (25)."},{"issue":"7","key":"10.1016\/j.intimp.2022.108623_b0155","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2022.108623_b0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-019-1256-6","article-title":"Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era","volume":"14","author":"Byun","year":"2019","journal-title":"Radiat Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108623_b0165","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","article-title":"Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma","volume":"92","author":"Huang","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"10.1016\/j.intimp.2022.108623_b0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/1097-0142(197801)41:1<108::AID-CNCR2820410116>3.0.CO;2-Z","article-title":"Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation","volume":"41","author":"Maclennan","year":"1978","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.intimp.2022.108623_b0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/cns.12.14","article-title":"Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas","volume":"1","author":"Yovino","year":"2012","journal-title":"CNS Oncol."},{"key":"10.1016\/j.intimp.2022.108623_b0180","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920926822","article-title":"A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy","volume":"12","author":"Wang","year":"2020","journal-title":"Therapeutic advances in medical oncology."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:39:45Z","timestamp":1761586785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922001072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":36,"alternative-id":["S1567576922001072"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108623","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108623"}}